Accessibility Menu
Peijia Medical logo

Peijia Medical(SEHK) 9996

Market CapHK$3.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-79%
5 Year-77%
1 Year-31%
1 Month+28%
HK$5.02
-2.62%
-0.14Today
Peijia Medical last closing stock price
MetricPriceDate
Last closeHKD 5.152026-08-31
Peijia Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.2%HKD 5.322026-08-24
1 month+28.11%HKD 4.022026-07-31
3 month+9.11%HKD 4.722026-06-02
Year to date-14.31%HKD 6.012025-12-31
1 year-30.5%HKD 7.412025-08-29
3 year-29.06%HKD 7.262023-08-31
5 year-77.16%HKD 22.552021-09-01
Since inception-79.22%HKD 25.802020-05-15

Peijia Medical Financials at a Glance

Market Cap

HK$3.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.45B

Net Income (TTM)

-CN¥366.07M

EPS (TTM)

-HK$0.23

P/E Ratio

-22.29

Dividend

HK$0.00

Beta (Volatility)

-0.12 (Low)

Price

HK$5.02

Volume

183,000

Open

HK$5.16

Previous Close

HK$5.15

Daily Range

HK$5.00 - HK$5.16

52-Week Range

HK$3.73 - HK$7.89

Estimated Earnings Date

Apr 1, 2027

9996 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Peijia Medical

Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Founded in 2012 and headquartered in Suzhou, China, the company offers a diverse portfolio of products aimed at improving patient outcomes in cardiovascular and neurovascular treatments.

Products and Services
  • Transcatheter aortic valve replacement systems, including TaurusOne and TaurusElite
  • Neurointerventional devices such as Jasper and Presgo detachable coils
  • Complementary devices like TaurusAtlas transfemoral balloon catheter and TaurusExplora guidewire
Growth Outlook
  • Increasing demand for minimally invasive procedures drives market growth
  • Expansion into international markets enhances revenue potential
  • Continuous investment in R&D supports innovative product development
Financial Highlights
  • Recent quarterly revenue of 359.49 million CNY, showing a steady increase
  • Gross profit margin of 66.32% in the latest quarter indicates strong operational efficiency
  • Cash and short-term investments totaled 610.52 million CNY, providing liquidity for growth
Peijia Medical Limited is positioned in a growing industry with a focus on innovative medical solutions. The company's diverse product offerings cater to critical healthcare needs, particularly in cardiovascular and neurovascular treatments. Recent financial performance reflects a positive trend, with increasing revenues and a solid gross profit margin, indicating effective cost management. The strong cash position allows for continued investment in research and development, which is essential for maintaining a competitive edge in the medical device market. As the demand for advanced medical technologies rises, Peijia Medical is well-placed to capitalize on these opportunities, making it an intriguing option for potential investors.
AI Generated • Aug 12, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,022

CEO

Yi Zhang, PhD

Website

www.peijiamedical.com

Headquarters

Suzhou, JS 215028, CN

9996 Financials

Key Financial Metrics (TTM)

Gross Margin

66.79%

Operating Margin

-12.78%

Net Income Margin

-18.11%

Return on Equity

-7.65%

Return on Capital

-8.72%

Return on Assets

-4.84%

Earnings Yield

-4.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$3.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

672.19M

Volume

183.00K

Avg. Volume

983.38K

Financials (TTM)

Gross Profit

CN¥982.13M

Operating Income

-CN¥322.35M

EBITDA

-CN¥197.23M

Operating Cash Flow

CN¥26.41M

Capital Expenditure

-CN¥436.49M

Free Cash Flow

-CN¥410.07M

Cash & ST Invst.

CN¥810.97M

Total Debt

CN¥652.57M

Peijia Medical Performance Analysis

Peijia Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 291,688,22777.3%
20232023-12-31CNY 487,443,34767.1%
20242024-12-31CNY 667,321,34336.9%
20252025-12-31CNY 773,124,17515.9%
Peijia Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-314.3%
Q22025-06-3012.4%
Q42025-12-311.7%
Q22026-06-3016.5%
Peijia Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.70-32.6%
20232023-12-31CNY -0.64-9.4%
20242024-12-31CNY -0.37-42.5%
20252025-12-31CNY -0.33-9.7%
Peijia Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-140.0%
Q22025-06-3058.3%
Q42025-12-31-100.0%
Q22026-06-3094.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥418.64M

+39.0%

Gross Profit

CN¥281.32M

+28.5%

Gross Margin

67.20%

N/A

Market Cap

HK$3.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$3.39M

N/A

Employees

1,022

N/A

Net Income

-CN¥7.48M

+89.5%

EBITDA

CN¥68.88M

+207.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥810.97M

-12.8%

Total Debt

CN¥652.57M

+158.2%

Accounts Receivable

CN¥125.54M

+538.2%

Inventory

CN¥152.47M

-14.8%

Long Term Debt

CN¥262.29M

+19.5%

Short Term Debt

CN¥392.24M

+1082.4%

Return on Assets

-4.84%

N/A

Return on Invested Capital

-4.52%

N/A

Free Cash Flow

CN¥0.00

+100.0%

Operating Cash Flow

CN¥0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 9996

What is the current price of Peijia Medical?

Peijia Medical is trading at HK$5.02 per share.

What is the 52-week range for Peijia Medical?

Over the past 52 weeks, Peijia Medical has traded between HK$3.73 and HK$7.89.

How much debt does Peijia Medical have?

As of the most recent reporting period, Peijia Medical reported total debt of CN¥494.57M.

How much cash does Peijia Medical have on hand?

Peijia Medical reported CN¥653.51M in cash and cash equivalents in its most recent financial results.

What is Peijia Medical’s dividend yield?

Peijia Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services